Literature DB >> 27668056

Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma.

Loretta Fala.   

Abstract

Entities:  

Year:  2016        PMID： 27668056      PMCID： PMC5013851     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

1.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.

Authors: 
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

2.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

3.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  3 in total
  12 in total

1.  Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.

Authors:  Erminia Ridolo; Francesco Pucciarini; Maria Cristina Nizi; Eleni Makri; Paola Kihlgren; Lorenzo Panella; Cristoforo Incorvaia
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

2.  Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.

Authors:  Shoko Isoyama; Nobuhisa Ishikawa; Kosuke Hamai; Mirai Matsumura; Hiroki Kobayashi; Akio Nomura; Sayaka Ueno; Takuya Tanimoto; Hiroyuki Maeda; Hiroshi Iwamoto; Noboru Hattori
Journal:  Intern Med       Date:  2022-06-01       Impact factor: 1.282

Review 3.  Current State and Future of Biologic Therapies in the Treatment of Asthma in Children.

Authors:  Elissa M Abrams; Allan B Becker; Stanley J Szefler
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2018-09-17       Impact factor: 1.349

4.  Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.

Authors:  Amelia Licari; Sara Manti; Riccardo Castagnoli; Giuseppe Fabio Parisi; Carmelo Salpietro; Salvatore Leonardi; Gian Luigi Marseglia
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

Review 5.  Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling.

Authors:  Grzegorz Kardas; Piotr Kuna; Michał Panek
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

Review 6.  A Review of Respiratory Biologic Agents in Severe Asthma.

Authors:  Nathaniel Johnson; Blessy Varughese; Marianne A De La Torre; Salim R Surani; George Udeani
Journal:  Cureus       Date:  2019-09-18

7.  A Unique Case of Non-cardiac Chest Pain Caused by Mepolizumab: Case Report and Review of the Literature.

Authors:  Parker M Korbitz; John P Gallagher; Neil Bhogal; Wuttiporn Manatsathit
Journal:  J Neurogastroenterol Motil       Date:  2020-01-30       Impact factor: 4.924

8.  Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.

Authors:  Luciana Kase Tanno; Pascal Demoly; Bryan Martin; Jonathan Berstein; Mario Morais-Almeida; Michael Levin; Alessandro Fiocchi; Mario Sánchez-Borges; Luis R Caraballo; Gary Wong; José Antonio Ortega-Martell; Philip Rouadi; Anahí Yáñez; Liang Lu Wang; David B Peden; Manana Chikhladze; Sandra N González-Díaz; Jean-François Fontaine; James Sublett; Yoon-Seok Chang; Giovanni Passalacqua; Ignacio J Ansotegui; Motohiro Ebisawa; Gianenrico Senna; Marco Caminati
Journal:  World Allergy Organ J       Date:  2021-01-31       Impact factor: 4.084

Review 9.  Targeted therapy in eosinophilic chronic obstructive pulmonary disease.

Authors:  Mathieu Fieldes; Chloé Bourguignon; Said Assou; Amel Nasri; Aurélie Fort; Isabelle Vachier; John De Vos; Engi Ahmed; Arnaud Bourdin
Journal:  ERJ Open Res       Date:  2021-04-12

Review 10.  Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.

Authors:  Molly Easter; Seth Bollenbecker; Jarrod W Barnes; Stefanie Krick
Journal:  Int J Mol Sci       Date:  2020-09-21       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.